GSK to buy cancer company for USD 1.9bn

Glaxosmithkline and Sierra Oncology have agreed to terms that would bring the Canadian biotech firm into British hands.
Photo: Toby Melville/REUTERS / X90004
Photo: Toby Melville/REUTERS / X90004
by MIKKEL AABENHUS HEMMINGSEN, translated by daniel pedersen

Another acquisition is taking place in the pharmaceutical industry at large, as Glaxosmithkline (GSK) and Sierra Oncology have announced on Wednesday that they have reached an agreement, a press release reports.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading